A medical-device award is not a medical-device approval. That distinction is particularly important for Lampsy Health, a Portuguese startup whose progress at Web Summit week drew attention to a proposed technology for healthcare.

Lampsy reached the KPMG Global Tech Innovator final during Web Summit 2026. Its presence in the competition was recognition of business and technical promise. It did not establish that the product held a CE mark or was ready for unrestricted clinical use.

What did Lampsy achieve in Lisbon?

The company was part of the global KPMG innovation competition, which concluded during the storm-affected Lisbon conference week. The global prize ultimately went to Austria's AURIMOD, with TissueLabs second. Lampsy was a global finalist following its Portugal national win.

KPMG's Portugal national-finalist field also included BloodFlow and Octo Health, reflecting the range of health-related companies in the selection pathway.

What is the product, and what evidence is available?

Lampsy's proposition belongs in the medical-technology category, where claims about a device's use and status need to be separated carefully. The proposed device remains in development without CE marking, with clinical validation and European certification part of its pathway.

For regulated medical devices in Europe, CE marking reflects a specific conformity process tied to intended purpose and applicable requirements. Competition recognition and clinical or regulatory milestones have different roles in a product's development.

The questions a hospital buyer would need answered include the product's intended use, risk class, clinical evaluation, quality-management arrangements, and which claims are supported by actual testing.

What comes next for the technology

Health technology frequently travels through several kinds of validation at once. A pitch jury may find a concept compelling. Early users may like a prototype. Engineers may demonstrate technical feasibility. Yet none of these outcomes automatically proves clinical benefit or regulatory conformity.

Technical promise, clinical validation and regulatory readiness are separate milestones. Competition recognition addresses the company's proposition; clinical adoption depends on evidence about the product itself.

Lampsy's KPMG appearance is a meaningful visibility milestone. A documented regulatory and clinical pathway would be the next one to watch.

Booths and attendees on day one of Web Summit 2026. The photo does not show Lampsy Health. Photo by Eakin Howard/Web Summit via Sportsfile, CC BY 4.0, cropped
Booths and attendees on day one of Web Summit 2026. The photo does not show Lampsy Health. Photo by Eakin Howard/Web Summit via Sportsfile, CC BY 4.0, cropped

Why a bedside lamp is an interesting epilepsy-monitoring idea

Seizure monitoring presents a practical problem for families and carers. A device can only help if people can use it consistently. Wearable products may provide useful information but can become difficult to tolerate or remember, especially overnight. A bedside device offers a different trade-off: it does not need to be attached to the body, but it must identify relevant events reliably from the environment around the person.

Lampsy Health's proposed lamp uses computer vision to detect movement patterns associated with convulsive seizures and alert a trusted contact. That description is important because it is narrower than the general claim that an AI lamp can monitor epilepsy. Different seizure types can look very different. A system designed around visible convulsive movement should not automatically be presumed capable of detecting events that do not produce the same observable pattern.

The product is intriguing for precisely that reason. It addresses a defined problem with a form factor that may fit naturally into a bedroom. It also introduces challenging questions about camera placement, lighting, blankets, movement during sleep and other people or objects within view. A realistic evaluation would need to show how the system handles ordinary bedrooms, not only carefully selected demonstrations.

Detection accuracy is only part of the safety story

KPMG materials cited a 97% accuracy figure for Lampsy, according to published reporting. That number remains a company or programme claim, not an independently verified clinical outcome in the reviewed materials. Without the evaluation design, the percentage cannot tell a family or clinician how the device will behave over weeks of nightly use.

For a detection system, sensitivity and false alarms are both important. Missing an event may undermine the purpose of the monitor. Too many false alarms can exhaust carers and reduce trust, even if the system correctly identifies many events in a controlled test. The balance between those outcomes depends on how the device is intended to be used and what response is expected after an alert.

The denominator matters. A study with many hours in which no seizure occurred can produce reassuring-looking summary figures while offering limited evidence about how often actual seizures are detected. A reader would need to know the number and nature of observed events, the reference used to confirm them, the participant population and the settings in which the device was assessed.

It would also be important to understand which events the product explicitly does not attempt to detect. Families need plain information about the limits of the device. Technology that is presented as additional monitoring should not inadvertently persuade people that it replaces clinical care, existing safety measures or professional advice.

Navigating the medical-device pathway

The company's regulatory pathway depends on the precise claims and intended use of its monitoring technology. Classification, clinical evaluation and conformity assessment are linked steps in that development.

European medical-device classification depends on intended use and the applicable rules. A team may have a preliminary view of its classification, but that is best distinguished from a settled regulatory outcome if certification has not occurred. Nor does a prize or a hospital relationship constitute a CE mark.

Técnico reported a €230,000 investment in May 2025 directed toward clinical validation and European certification. That provides useful context: it suggests the team recognised that validation and regulatory work were steps to complete. It does not establish that those steps were finished by Web Summit 2026.

The strongest next announcement would clarify the intended-use statement, the classification the company is pursuing, the evaluation milestones and what supporting evidence is available. Investors, hospitals and families should be able to distinguish a promising prototype from an authorised product ready for the specific use being claimed.

Attendees at Centre Stage on day three of Web Summit 2026. The photo does not show Lampsy Health. Photo by Ramsey Cardy/Web Summit via Sportsfile, CC BY 4.0, cropped
Attendees at Centre Stage on day three of Web Summit 2026. The photo does not show Lampsy Health. Photo by Ramsey Cardy/Web Summit via Sportsfile, CC BY 4.0, cropped

Working with hospitals to develop the solution

Published reporting identifies a claim of six public-hospital partnerships in KPMG materials. Partnerships can be meaningful, but the word covers several arrangements. A hospital might provide expert feedback, contribute to research, help recruit participants, evaluate a prototype or purchase and routinely use a commercial device. These activities are different, and they demonstrate different levels of maturity.

A company should be able to explain what the partnership involves without disclosing confidential arrangements. Does it mean a feasibility study is planned? Are users participating in an evaluation? Have the institutions agreed to study protocols? Is there an independently reported result? Each answer would help readers understand the stage of development.

The value of a hospital relationship is often greatest when it improves the design before commercial launch. Clinical teams can identify problems that do not appear in a laboratory, including confusing alerts, unsuitable workflows and practical barriers to use. If that feedback leads to a better product, the partnership may be valuable even before a clinical efficacy study is complete.

But it would be inaccurate to turn a partnership count into a claim of real-world clinical effectiveness. The work has to be described and evaluated on its own terms.

The question of privacy in a bedroom

A camera-based system in a bedroom raises understandable privacy questions, regardless of whether the camera is concealed inside a familiar object. Users and families need to know what the device records, where processing happens, whether images are stored and who can access them. If the system operates locally, that may be a useful design feature, but the details still matter.

The device must also fit real family routines. Who receives an alert? What happens if that person's phone is off? Can more than one caregiver be notified? How are alerts distinguished from routine movement? Answering those questions could make as much difference to adoption as refining the algorithm.

What reaching the KPMG final actually means

Lampsy was Portugal's national winner and reached the global final, which took place under unusual circumstances after the weather disruption. It did not finish in the global top three. That is still a notable achievement for an early medical-technology team, particularly one emerging from Portuguese research institutions.

Recognition may help attract partners and funding. It cannot take the place of the difficult work that follows: a clearly described product, rigorous clinical evaluation, suitable privacy controls and completion of the relevant regulatory pathway. Those are the milestones that matter to the people who might one day rely on the lamp.

For Lampsy's non-worn monitoring approach, the practical goal is reliable detection of the intended events in realistic conditions, with an acceptable burden of false alarms. Clinical evaluation and the relevant regulatory pathway are the next steps toward routine use.